AustralieFrV1, Main, Exploration, bibRecord, 00C938

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer

Identifieur interne : 00C938 ( Main/Exploration ); précédent : 00C937; suivant : 00C939

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer

Auteurs : M. Friedlander [Australie] ; M. J. Millward [Australie] ; D. Bell [Australie] ; R. Bugat [France] ; P. Harnett [Australie] ; J. A. Moreno ; L. Campbell [France] ; C. Varette ; V. Ripoche ; L. Kayitalire

Source :

Annals of Oncology [ 0923-7534 ] ; 1998-12.

RBID : ISTEX:48AFFA941B44F6EEED553E360FBEAB82EAF54366

Descripteurs français

Pascal (Inist)
- Anticancéreux, Chimiothérapie, Cisplatine, Essai clinique phase II, Femelle, Fluor Composé organique, Gemcitabine, Homme, Ovaire, Platine II Complexe, Pyrimidine nucléoside, Récidive, Stade avancé, Toxicité, Traitement rattrapage, Tumeur maligne, Voie intraveineuse.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Advanced stage, Antineoplastic agent, Chemotherapy, Cisplatin, Female, Fluorine Organic compounds, Gemcitabine, Human, Intravenous administration, Malignant tumor, Ovary, Phase II trial, Platinum II Complexes, Pyrimidine nucleoside, Relapse, Salvage treatment, Toxicity.

Abstract

Background: Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment. Gemcitabine, a nucleoside analogue, is active against a range of solid tumors. This phase II study investigated the activity of single-agent gemcitabine in patients with recurrent ovarian cancer. Patients and methods: Thirty-eight patients with FIGO stage III (34%) or IV (64%) ovarian cancer who were previously treated with platinum-containing regimens were enrolled. Patients received 1200 mg/m2 gemcitabine on days 1, 8 and 15 of a 28-day cycle. Results: Patients completed an average of 3.6 cycles. Two complete and three partial responses were seen in 36 evaluable patients, for an overall response rate of 13.9% (95% CI: 4.7%–29.5%). The median survival time was 6.7 months. Toxicities were generally mild. The most common were grade 3–4 neu-tropenia and grade 3 leukopenia reported in 23.7% and 10.5% of patients, respectively. One patient had grade 4 pulmonary toxicity. Conclusion: Single-agent gemcitabine is active and well tolerated in patients with recurrent ovarian cancer.

Url:

https://api.istex.fr/document/48AFFA941B44F6EEED553E360FBEAB82EAF54366/fulltext/pdf

DOI: 10.1023/A:1008469212268

Affiliations:

Australie, France

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer</title>
<author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name>
</author>
<author><name sortKey="Millward, M J" sort="Millward, M J" uniqKey="Millward M" first="M. J." last="Millward">M. J. Millward</name>
</author>
<author><name sortKey="Bell, D" sort="Bell, D" uniqKey="Bell D" first="D." last="Bell">D. Bell</name>
</author>
<author><name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
</author>
<author><name sortKey="Harnett, P" sort="Harnett, P" uniqKey="Harnett P" first="P." last="Harnett">P. Harnett</name>
</author>
<author><name sortKey="Moreno, J A" sort="Moreno, J A" uniqKey="Moreno J" first="J. A." last="Moreno">J. A. Moreno</name>
</author>
<author><name sortKey="Campbell, L" sort="Campbell, L" uniqKey="Campbell L" first="L." last="Campbell">L. Campbell</name>
</author>
<author><name sortKey="Varette, C" sort="Varette, C" uniqKey="Varette C" first="C." last="Varette">C. Varette</name>
</author>
<author><name sortKey="Ripoche, V" sort="Ripoche, V" uniqKey="Ripoche V" first="V." last="Ripoche">V. Ripoche</name>
</author>
<author><name sortKey="Kayitalire, L" sort="Kayitalire, L" uniqKey="Kayitalire L" first="L." last="Kayitalire">L. Kayitalire</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:48AFFA941B44F6EEED553E360FBEAB82EAF54366</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1023/A:1008469212268</idno>
<idno type="url">https://api.istex.fr/document/48AFFA941B44F6EEED553E360FBEAB82EAF54366/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000D61</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D61</idno>
<idno type="wicri:Area/Istex/Curation">000D61</idno>
<idno type="wicri:Area/Istex/Checkpoint">002297</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002297</idno>
<idno type="wicri:doubleKey">0923-7534:1998:Friedlander M:a:phase:ii</idno>
<idno type="wicri:Area/Main/Merge">00D975</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:99-0170681</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">006418</idno>
<idno type="wicri:Area/PascalFrancis/Curation">006C36</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">006523</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">006523</idno>
<idno type="wicri:doubleKey">0923-7534:1998:Friedlander M:a:phase:ii</idno>
<idno type="wicri:Area/Main/Merge">00DE10</idno>
<idno type="wicri:Area/Main/Curation">00C938</idno>
<idno type="wicri:Area/Main/Exploration">00C938</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer</title>
<author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Prince of Wales Hospital Randwick</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Australie</country>
</affiliation>
<affiliation><wicri:noCountry code="syntax">???</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Australie</country>
</affiliation>
</author>
<author><name sortKey="Millward, M J" sort="Millward, M J" uniqKey="Millward M" first="M. J." last="Millward">M. J. Millward</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Peter Maccallum Cancer Institute East Melbourne</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bell, D" sort="Bell, D" uniqKey="Bell D" first="D." last="Bell">D. Bell</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Roval North Shore Hospital St. Leonards</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Centre Claudius Regaud Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Harnett, P" sort="Harnett, P" uniqKey="Harnett P" first="P." last="Harnett">P. Harnett</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Westmead Hospital Westmead</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moreno, J A" sort="Moreno, J A" uniqKey="Moreno J" first="J. A." last="Moreno">J. A. Moreno</name>
<affiliation><wicri:noCountry code="no comma">Hospital Universitatio Virgen del Rocio Sevilla</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Campbell, L" sort="Campbell, L" uniqKey="Campbell L" first="L." last="Campbell">L. Campbell</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Hopital Saint-Antoine Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Varette, C" sort="Varette, C" uniqKey="Varette C" first="C." last="Varette">C. Varette</name>
<affiliation><wicri:noCountry code="no comma">Lilly Australia</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Ripoche, V" sort="Ripoche, V" uniqKey="Ripoche V" first="V." last="Ripoche">V. Ripoche</name>
<affiliation><wicri:noCountry code="no comma">Lilly France</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kayitalire, L" sort="Kayitalire, L" uniqKey="Kayitalire L" first="L." last="Kayitalire">L. Kayitalire</name>
<affiliation><wicri:noCountry code="no comma">Lilly France</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Oncology</title>
<idno type="ISSN">0923-7534</idno>
<idno type="eISSN">1569-8041</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="published" when="1998-12">1998-12</date>
<biblScope unit="volume">9</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1343">1343</biblScope>
<biblScope unit="page" to="1345">1345</biblScope>
</imprint>
<idno type="ISSN">0923-7534</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antineoplastic agent</term>
<term>Chemotherapy</term>
<term>Cisplatin</term>
<term>Female</term>
<term>Fluorine Organic compounds</term>
<term>Gemcitabine</term>
<term>Human</term>
<term>Intravenous administration</term>
<term>Malignant tumor</term>
<term>Ovary</term>
<term>Phase II trial</term>
<term>Platinum II Complexes</term>
<term>Pyrimidine nucleoside</term>
<term>Relapse</term>
<term>Salvage treatment</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Anticancéreux</term>
<term>Chimiothérapie</term>
<term>Cisplatine</term>
<term>Essai clinique phase II</term>
<term>Femelle</term>
<term>Fluor Composé organique</term>
<term>Gemcitabine</term>
<term>Homme</term>
<term>Ovaire</term>
<term>Platine II Complexe</term>
<term>Pyrimidine nucléoside</term>
<term>Récidive</term>
<term>Stade avancé</term>
<term>Toxicité</term>
<term>Traitement rattrapage</term>
<term>Tumeur maligne</term>
<term>Voie intraveineuse</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background: Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment. Gemcitabine, a nucleoside analogue, is active against a range of solid tumors. This phase II study investigated the activity of single-agent gemcitabine in patients with recurrent ovarian cancer. Patients and methods: Thirty-eight patients with FIGO stage III (34%) or IV (64%) ovarian cancer who were previously treated with platinum-containing regimens were enrolled. Patients received 1200 mg/m2 gemcitabine on days 1, 8 and 15 of a 28-day cycle. Results: Patients completed an average of 3.6 cycles. Two complete and three partial responses were seen in 36 evaluable patients, for an overall response rate of 13.9% (95% CI: 4.7%–29.5%). The median survival time was 6.7 months. Toxicities were generally mild. The most common were grade 3–4 neu-tropenia and grade 3 leukopenia reported in 23.7% and 10.5% of patients, respectively. One patient had grade 4 pulmonary toxicity. Conclusion: Single-agent gemcitabine is active and well tolerated in patients with recurrent ovarian cancer.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
</country>
</list>
<tree><noCountry><name sortKey="Kayitalire, L" sort="Kayitalire, L" uniqKey="Kayitalire L" first="L." last="Kayitalire">L. Kayitalire</name>
<name sortKey="Moreno, J A" sort="Moreno, J A" uniqKey="Moreno J" first="J. A." last="Moreno">J. A. Moreno</name>
<name sortKey="Ripoche, V" sort="Ripoche, V" uniqKey="Ripoche V" first="V." last="Ripoche">V. Ripoche</name>
<name sortKey="Varette, C" sort="Varette, C" uniqKey="Varette C" first="C." last="Varette">C. Varette</name>
</noCountry>
<country name="Australie"><noRegion><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name>
</noRegion>
<name sortKey="Bell, D" sort="Bell, D" uniqKey="Bell D" first="D." last="Bell">D. Bell</name>
<name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name>
<name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name>
<name sortKey="Harnett, P" sort="Harnett, P" uniqKey="Harnett P" first="P." last="Harnett">P. Harnett</name>
<name sortKey="Millward, M J" sort="Millward, M J" uniqKey="Millward M" first="M. J." last="Millward">M. J. Millward</name>
</country>
<country name="France"><noRegion><name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
</noRegion>
<name sortKey="Campbell, L" sort="Campbell, L" uniqKey="Campbell L" first="L." last="Campbell">L. Campbell</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00C938 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00C938 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:48AFFA941B44F6EEED553E360FBEAB82EAF54366
   |texte=   A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.